介入治疗对胰腺癌患者血清sTNFR-Ⅰ和IAP的影响

Effect of intra arterial chemotherapy on serum sTNFR-Ⅰand IAP of patients with pancreatic cancer

目的 探讨胰腺癌患者介入治疗前后血清可溶性肿瘤坏死因子受体 Ⅰ (sTNFR Ⅰ )和免疫抑制酸性蛋白 (IAP)水平的变化及其临床意义。方法 分别用双抗体夹心酶联免疫法 (ELISA)和单向免疫扩散法测定 5 5例中晚期胰腺癌患者行动脉栓塞化疗前后血清sTNFR Ⅰ和IAP的改变 ,并与健康对照组比较分析。结果 胰腺癌组介入治疗前sTNFR Ⅰ和IAP均增高 ,与对照组比较差异有显著性(P <0 .0 1) ;行化疗栓塞术后 ,患者血清sTNFR Ⅰ和IAP均降低 ,治疗前后差异有显著性 (P <0 .0 5 ) ;应用免疫调节剂组较未用组血清sTNFR Ⅰ和IAP均下降更显著 (P <0 .0 5 )。结论 检测胰腺癌患者血清sTNFR Ⅰ和IAP的水平 ,有助于了解患者的免疫状况 ,介入治疗能改善机体免疫功能 。

Objective To study the changes of serum soluble tumor necrosis factor receptor Ⅰ (sTNFR Ⅰ) and immunosuppressive acidic protein (IAP) of patients with pancreatic cancer before and after intra arterial chemotherapy and evaluate their significance. Methods The levels of sTNFR Ⅰ and IAP of 55 cases with pancreatic cancer before and after intra arterial chemotherapy were measured by enzyme linked immunosorbent assay (ELISA) and one direction immunodiffusion test respectively and compared them with those of healthy controls. Results The levels of sTNFR Ⅰ and IAP of patients with pancreatic cancer before intra arterial chemotherapy were higher than those of healthy controls ( P <0.01). After intra arterial chemotherpy, the levels of sTNFR 1 and IAP were declined ( P <0.05). The effects of the group with combined immune therapy (r IL 2 and r IF) were more obvious than those of the group without the latter( P < 0.05 ).Conclusions Measuring sTNFR 1 and IAP is helpful to know the patients' immune state. The method of intra arterial chemotherapy can improve immune function of the patients with pancreatic cancer and has more significant effects in the group of combination with suitable immune therapy.